Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment.

[1]  E. Souied,et al.  INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION COMPLICATING PATHOLOGIC MYOPIA , 2010, Retina.

[2]  M. L. Cachulo,et al.  INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION: 12-Month Results , 2010, Retina.

[3]  I. Mantel,et al.  Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  T. Lai,et al.  INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA , 2009, Retina.

[5]  J. Monés,et al.  Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results , 2009, Eye.

[6]  F. Allievi,et al.  Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. , 2009, American journal of ophthalmology.

[7]  Y. Tano,et al.  Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. , 2009, American journal of ophthalmology.

[8]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[9]  J. Pulido,et al.  Pharmacokinetics of intravitreal ranibizumab (Lucentis). , 2007, Ophthalmology.

[10]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[11]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[12]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[13]  K. Bartz-Schmidt,et al.  Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. , 2006, American journal of ophthalmology.

[14]  W. Brannath,et al.  Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. , 2005, American journal of ophthalmology.

[15]  M. Mochizuki,et al.  Characteristics of patients with a favorable natural course of myopic choroidal neovascularization , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[16]  M. Mochizuki,et al.  Myopic choroidal neovascularization: a 10-year follow-up. , 2003, Ophthalmology.

[17]  Jennifer I. Lim,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. , 2003, Ophthalmology.

[18]  George A. Williams,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. , 2001, Ophthalmology.

[19]  G. Soubrane,et al.  Etiology of choroidal neovascularization in young patients. , 1996, Ophthalmology.

[20]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.